Long Shortz with Rhythm Biosciences: Inside ColoSTAT’s road to market

Tylah Tully chats with Rhythm Biosciences (ASX:RHY) CEO David Atkins about the company’s mission to make cancer a more treatable condition through earlier detection—starting with bowel cancer.

Rhythm is developing ColoSTAT, a groundbreaking blood-based diagnostic test designed to detect the likelihood of bowel cancer more easily and effectively than current stool-based methods.

He discusses the recent redevelopment of the test, which led to significant improvements in ease of use, cost, speed, and clinical performance.

Watch the video to hear more.

This video was developed in collaboration with Rhythm Biosciences, a Stockhead client at the time of publishing.

The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.